Theriva Biologics, Inc.TOVXNYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank0
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P0
Near historical low
vs 3Y Ago
-1.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -83.10% |
| Q2 2025 | 682.84% |
| Q1 2025 | -3.64% |
| Q4 2024 | -35.62% |
| Q3 2024 | 56.92% |
| Q2 2024 | -22.54% |
| Q1 2024 | 15.28% |
| Q4 2023 | -9.33% |
| Q3 2023 | -19.65% |
| Q2 2023 | 2.45% |
| Q1 2023 | 2.13% |
| Q4 2022 | -10.80% |
| Q3 2022 | 56.78% |
| Q2 2022 | -6.89% |
| Q1 2022 | -33.43% |
| Q4 2021 | 90.79% |
| Q3 2021 | 3.00% |
| Q2 2021 | -10.85% |
| Q1 2021 | 23.07% |
| Q4 2020 | -3.68% |
| Q3 2020 | -6.92% |
| Q2 2020 | -7.68% |
| Q1 2020 | 8.57% |
| Q4 2019 | 16.85% |
| Q3 2019 | 5.17% |
| Q2 2019 | -9.53% |
| Q1 2019 | -3.99% |
| Q4 2018 | -18.45% |
| Q3 2018 | 3.00% |
| Q2 2018 | -11.67% |
| Q1 2018 | -20.08% |
| Q4 2017 | 18.89% |
| Q3 2017 | 3.71% |
| Q2 2017 | -21.34% |
| Q1 2017 | -39.86% |
| Q4 2016 | 65.87% |
| Q3 2016 | -2.42% |
| Q2 2016 | -11.50% |
| Q1 2016 | -4.30% |
| Q4 2015 | 58.04% |